Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

Acquisition Value:
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, making it the largest biopharma merger-and-acquisition deal announced in two years24.

Portfolio Expansion:
The acquisition enhances Johnson & Johnson's neuroscience portfolio with lumateperone (CAPLYTA), a once-daily oral therapy approved for treating adults with schizophrenia and depressive episodes associated with bipolar I or II disorder24.

Strategic Growth:
The deal is seen as a strategic near- and long-term growth catalyst for Johnson & Johnson, offering compelling value to patients, health systems, and shareholders24.

Regulatory and Closing Conditions:
The transaction is expected to close later in 2025, subject to regulatory approvals, approval by Intra-Cellular Therapies’ stockholders, and other customary closing conditions24.

Future Potential:
CAPLYTA has shown robust efficacy, proven safety, and favorable tolerability across its approved indications, with potential to become a new standard of care for prevalent and debilitating mental health disorders24.

Additional Trials:
Additional Phase III trials are underway with CAPLYTA in bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), and positive topline results have been announced for preventing relapse in adults with schizophrenia2.

Sources:

2. https://www.genengnews.com/gen-edge/jj-to-acquire-intra-cellular-for-14-6b/

4. https://www.psychiatrictimes.com/view/johnson-johnson-acquired-intra-cellular-therapies